Companies › TRB Chemedica
1 active drug program in 1 registered trial: 1 Phase 3; Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Diacerein (Artrodar) Anti-catabolic agent; inhibits interleukin-1 (IL-1) production and cartilage degradation | – | Phase 3 | Knee Osteoarthritis | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04318041 | Diacerein (Artrodar) | Phase 3 | Knee Osteoarthritis | Immunology | Dec 2026 |
No annotated target.
–
Pharvaris Netherlands AUG Therapeutics Lynk Pharmaceuticals Fujian Mindong Rejuvenation Pharmaceutical Jiangsu Genscend Biopharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.